July 10, 2020 - 07:19

Waiver to the Golden Power Condition

July 9, 2020 - 13:03

Orchard-MolMed parternship

July 7, 2020 - 15:14

Golden Power Condition

June 25, 2020 - 19:41

Resignation auditor

June 8, 2020 - 18:04

Issuer Statement pursuant 103 TUF integration

May 29, 2020 - 23:03

Issuer Statement approval pursuant 103 TUF

May 29, 2020 - 23:00

Press release - Approval and publication of the offer document

May 18, 2020 - 17:31

Publication of the Minutes (in Italian) of the OGM held on April 27, 2020

May 11, 2020 - 18:02

Update on the timing for the approval of ACG Offer Document

May 11, 2020 - 16:01

MolMed Board of Directors approves first quarter 2020 financial results

April 29, 2020 - 18:29

Update on the timing for the approval of ACG Offer Document

April 27, 2020 - 16:51

The Shareholders’ meeting approved the 2019 Financial Statement.

April 15, 2020 - 13:03

Shareholders meeting April 27 2020: Guide to the online filing and transmission of the proxy to Computershare S.p.A. (RECOMMENDED PROCEDURE)

April 14, 2020 - 18:46

The Board of Directors, based on the scientific evidence from the experiments on early-stage pre-clinical products, decided to suspend the investments in these projects.

April 10, 2020 - 20:27

Suspension of the terms of the administrative procedures extended until 15 May 2020 by Decree Law no. 23 of 8 April 2020

April 6, 2020 - 19:20

Notice of publication of the Annual Report 2019 and other documents for the Shareholders’ meeting on April 27th, 2020.

April 2, 2020 - 20:48

OFFER DOCUMENT of AGC FILED WITH CONSOB

March 31, 2020 - 16:37

Corporate bylaw update

March 23, 2020 - 10:49

Abstract of notice (in Italian) of Shareholders' agreement between AGC and Fininvest pursuant Art 122 Decree 58/98 (Consolidated Law on Finance) and Art. 129, comma 1 Issuers Regulation ("Regolamento Emittenti" n. 11971 May, 14 1999)

March 20, 2020 - 16:30

Essential information on AGC/Fininvest Agreement, pursuant to Art. 130 of Issuers' Regulation (in Italian)

March 18, 2020 - 16:18

MolMed signs a new multi-year agreement and announces the beginning of another collaboration in the field of rare diseases.

March 17, 2020 - 08:58

Notice pursuant to Art. 102

March 17, 2020 - 07:23

AGC Inc. announces the launch of a voluntary tender offer over all ordinary shares of MolMed S.p.A.

March 9, 2020 - 19:31

Board of Directors approved the 2019 Full Year financial results, which show a continuous and significant improvement

March 6, 2020 - 07:49

MolMed signs a multi-year agreement and announces the beginning of a new collaboration in the field of T cell therapies.

February 12, 2020 - 17:47

AIFA authorizes new areas of Bresso facility for GMP manufacturing of viral vectors

February 3, 2020 - 11:13

MolMed: the CAR-T CD44v6 clinical trial progress presented at the 2nd European CAR T Cell Meeting in Sitges, Barcelona.

January 29, 2020 - 15:18

Financial calendar 2020

December 18, 2019 - 12:01

The EIB supports MolMed investment in research, development and manufacturing for cancer and rare diseases innovative treatments.

November 20, 2019 - 18:07

Publication of the Interim financial report as of September 30th 2019

November 11, 2019 - 22:25

Board of Directors approves financial results for the nine months ended September 30 2019

October 10, 2019 - 18:08

MolMed informs on its decision to withdraw the Conditional Marketing Authorization of Zalmoxis

October 1, 2019 - 20:45

Lombardy Region approved the "agreement for innovation" scheme for the financing, together with the Ministry of Economic Development, of MolMed’s project proposal "New CAR therapies for the treatment of cancer patients"

September 12, 2019 - 14:04

MolMed to present its CDMO services at 2019 CAR-TCR Summit in Boston

August 1, 2019 - 11:16

Publication of the Half Year Financial Report (in Italian) as of 30 June 2019

July 29, 2019 - 19:22

Board of Directors approved IH19 results

June 27, 2019 - 18:32

MolMed announces the decision to suspend the enrollment of new patients in phase III study TK008 with Zalmoxis®.

May 24, 2019 - 15:46

The European Patent Office issued the decision to grant to Molmed a new patent on CAR technology.

May 22, 2019 - 16:46

Results of the independent study INGRID on NGR-hTNF potential in brain lymphomas published by Blood

May 20, 2019 - 12:10

MolMed at the World Advanced Therapies & Regenerative Medicine meeting on the strategies to enhance manufacturing of Cell & Gene therapies, and meet the increasing market demand in the field.

May 16, 2019 - 14:45

MolMed: Riccardo Palmisano reappointed Assobiotec President for the three-year period 2019-2022.

May 15, 2019 - 19:30

Publication of the Interim management report as of March 31st 2019

May 15, 2019 - 15:35

Publication of the Minutes of the OGM held on April 30th 2019

May 13, 2019 - 20:22

MolMed: Board of Directors approves first quarter 2019 financial results.

May 2, 2019 - 17:29

MolMed at the 22nd American Society of Gene and Cell Therapy (ASGCT) congress on continuous innovation in the production of viral vectors for clinical use.

April 30, 2019 - 18:18

MolMed: Shareholders meeting approved the Financial Statement 2018 and renewed Company’s boards.

April 25, 2019 - 23:55

MolMed at the “Cell & Gene Meeting on the Mediterranean” conference on the opportunities of price and reimbursement in the advanced therapies field.

April 9, 2019 - 19:56

Notice of publication of the Annual Report 2018 and other documents (in Italian) for the Shareholders’ meeting on April 30th, 2019

April 5, 2019 - 19:07

Lists of candidates for the appointment of the BoD and Board of Statutory auditors submitted

March 29, 2019 - 07:26

MolMed: Riccardo Palmisano reappointed representative of small and medium enterprises within the new Executive Council of the Lombardy Life Sciences Cluster.

March 20, 2019 - 08:17

MolMed received the authorization to start clinical investigation with CAR T CD44v6 cells in AML and MM

March 18, 2019 - 20:04

Board of Directors approved 2018 Full Year financial results

March 13, 2019 - 17:09

Partnership with Rocket Pharma in the field of rare genetic diseases extended to three new therapeutic indications.

March 7, 2019 - 15:01

MolMed and Genenta Science confirm and extend their partnership in the oncology field.

February 15, 2019 - 15:21

MolMed: the protocol of the in-man trial on CAR T CD44v6 presented at EHA (European Hematology Association) in Paris.

February 4, 2019 - 15:06

Germany confirms the reimbursement of Zalmoxis® at a price of 130,000€ per infusion

January 15, 2019 - 15:06

Financial calendar 2019

January 15, 2019 - 13:33

MolMed: opinion of the Transparency Commission of the French National Health Authority (HAS) on Zalmoxis® reimbursability in France.

November 16, 2018 - 18:28

PR_Minute of Shareholders Meeting held on Oct 25 and updated Corporate by Laws publication

November 12, 2018 - 23:07

Interim financial results as of September 30th 2018

November 12, 2018 - 21:18

MolMed and Dompé announce the mutual termination of the license and distribution agreement for Zalmoxis®

October 25, 2018 - 18:47

October 25th 2018 Ordinary and Extraordinary Shareholders Meeting Outcome

October 17, 2018 - 20:19

Results from a new study on CAR T CD44v6 in in-vivo experimental models of lung carcinoma and melanoma confirm the high therapeutic potential of MolMed’s therapy also in solid tumors. The results have been presented today at the ESGCT

October 12, 2018 - 18:58

MolMed: announcement with reference to the shareholders meeting of October 25th 2018.

September 29, 2018 - 18:00

MolMed participates at the first annual meeting of the International Academy for Clinical Hematology ("IACH"). The therapeutic potential of Zalmoxis® in haploidentical transplantation and of CAR T CD44v6 in blood tumours presented at the summit.

September 24, 2018 - 22:25

Carlo Incerti succeeds to Claudio Bordignon as Chairman of the Board. The BoD calls Shareholders’ Meeting to resolve on capital increase, within the limit of 10%, with the exclusion of the option rights.

September 11, 2018 - 08:08

MolMed appoints Mr. Salvatore Calabrese Chief Financial Officer

August 1, 2018 - 08:58

Publication of the Interim Financial Report at June 30th 2018

July 31, 2018 - 19:08

MolMed approves results at June 30th 2018, significantly improved compared to first half 2017. Zalmoxis update.

July 13, 2018 - 19:08

MolMed signs a new, three-year agreement for the development and supply of lentiviral vectors MolMed will provide GSK with vectors for the oncology field

June 29, 2018 - 19:37

Resignation of the Officer Responsible for the preparation of company financial reports

June 28, 2018 - 16:37

MolMed and AbCheck sign a three-year Master Agreement for the development of new CARs targeting novel tumor antigens

June 22, 2018 - 18:00

MolMed and Orchard Therapeutics extend their collaboration in the field of gene therapy for rare diseases

June 4, 2018 - 18:00

New and relevant data on the therapeutic potential of NGR-hTNF in brain lymphomas presented today at ASCO

May 31, 2018 - 18:00

MolMed and Glycostem announce the execution of a binding termsheet for the development and manufacturing of allogeneic CAR-NK therapies

May 30, 2018 - 18:00

Further data on the safety profile of CAR-T CD44v6 result from a study conducted by San Raffaele Hospital, published by the prestigious journal Nature Medicine

May 25, 2018 - 18:00

5th tranche of the share capital increase reserved to Société Générale (“SEF") completed

May 24, 2018 - 18:00

Utilization request concerning the 5th tranche of the share capital increase to be reserved to Société Générale ("SEF") submitted

May 17, 2018 - 18:00

Full results of NGR-hTNF trial in mesothelioma published by the leading research journal The Lancet Oncology. New clinical outcome of NGR-hTNF in brain lymphomas will be presented at ASCO.

May 11, 2018 - 18:00

2018 First Quarter Results

May 4, 2018 - 18:00

MolMed signs Master Service Agreement with Boston Children’s Hospital for the supply of lentiviral vectors

May 4, 2018 - 18:00

Publication of the minutes of Shareholders Meeting of April 12nd 2018

April 12, 2018 - 18:00

MolMed: the Shareholders’ Meeting approves 2017 Financial Statements

April 11, 2018 - 18:00

MolMed and Orchard Therapeutics announce the beginning of their collaboration in the field of gene therapy for rare diseases

March 21, 2018 - 18:00

Publication of documents for the annual general meeting to be held on April 12th, 2018

March 14, 2018 - 18:00

MolMed presents at the 8th Advanced Therapies Summit in Amsterdam

March 12, 2018 - 18:00

Call for the Shareholders’ Meeting on April, 12nd 2018

March 9, 2018 - 18:00

MolMed: Board of Directors approved Full Year 2017 Results

February 26, 2018 - 18:00

MolMed and Miltenyi Biotec: EMA approves the utilization of CliniMACS Prodigy® in the commercial manufacturing of Zalmoxis®

February 15, 2018 - 18:00

MolMed: AIFA Determina on reimbursement regime and market price for the proprietary cell therapy Zalmoxis® published on the Official Gazette

February 8, 2018 - 18:00

MolMed: Dompé exercises the option right to undertake the market access and commercialization activities for Zalmoxis® in Switzerland, Turkey and Australia.

January 30, 2018 - 18:00

Financial calendar 2018

January 16, 2018 - 18:00

Zalmoxis®: price & reimbursement dossier filed in Germany, where the product can be prescribed and reimbursed as of January 15th

December 13, 2017 - 18:00

AIFA set the reimbursement price for Zalmoxis® at EUR 149.000 per infusion, gross of discounts foreseen by law, and also established a flat fee per patient

November 14, 2017 - 18:00

MolMed: completed the fourth tranche of the share capital increase to be reserved to Société Générale

November 13, 2017 - 18:00

Submitted the utilization request concerning the fourth tranche of the share capital increase reserved to Société Générale

November 6, 2017 - 18:00

Board of Directors approved the first nine months financial report at September 30th, 2017

October 25, 2017 - 18:00

New relevant safety data of CD44v6 CAR-T cells will be presented at the 4th International Congress on Stem Cell Transplantation and Cellular Therapies Pdf

September 22, 2017 - 18:00

Completed the third tranche of the share capital increase reserved to Société Générale pursuant to the “SEF”

September 21, 2017 - 18:00

MolMed: submitted the utilization request concerning the third tranche of the share capital increase to be reserved to Société Générale pursuant to “SEF – Standby Equity Facility” agreement

September 7, 2017 - 18:00

MolMed will attend the 2nd EBMT INTERNATIONAL TRANSPLANT COURSE in Barcelona

August 8, 2017 - 18:00

MolMed completed the second tranche of the share capital increase reserved to Société Générale pursuant to the “SEF” agreement

August 7, 2017 - 18:00

MolMed submitted the utilization request concerning the second tranche of the share capital increase to be reserved to Société Générale pursuant to “SEF – Standby Equity Facility” agreement

July 27, 2017 - 18:00

MolMed and Cellectis signed a development and manufacturing agreement in the field of allogeneic CAR T-cells

July 27, 2017 - 18:00

Board of Directors approved the first hal-year financial report ended June 30th, 2017

July 26, 2017 - 18:00

MolMed and Dompé signed strategic commercialization and supply agreements for Zalmoxis® in Europe

July 3, 2017 - 18:00

MolMed S.p.A.: mandate of Liquidity Provider assigned to Mediobanca

June 30, 2017 - 18:00

MolMed and TTY Biopharm entered into an exclusive agreement to commercialise Zalmoxis® in certain Asian territories

June 1, 2017 - 18:00

MolMed provides update on Zafiride Conditional Marketing Authorisation application

May 8, 2017 - 18:00

MolMed’s Board of Directors reviewed business performance and approved Interim Results at March 31st, 2017

April 28, 2017 - 18:00

MolMed and Megapharm enter into a license and distribution agreement on Zalmoxis® in Israel Pdf

April 10, 2017 - 18:00

Outcome of shareholders’ meeting of April 10, 2017

March 6, 2017 - 18:00

MolMed’s Board of Directors approved the draft financial statements of FY 2016 and convened the shareholders’ meeting

February 27, 2017 - 18:00

MolMed and Rocket Pharma establish a collaboration agreement in the field of gene therapy for the treatment of Fanconi Anemia

February 7, 2017 - 18:00

MolMed and TTY Biopharm entered into a term sheet to commercialise Zalmoxis® in certain Asian territories

January 30, 2017 - 18:00

Financial calendar for fiscal year 2017

December 23, 2016 - 18:00

EMA has validated the submission of Conditional Marketing Authorisation for NGR-hTNF

December 20, 2016 - 18:00

Request submitted for first tranche of share capital increase reserved to Société Générale pursuant to SEF agreement

December 12, 2016 - 18:00

MolMed coordinates a CAR T-cell immunotherapy project awarded a 5.9 million Euro grant by the European Commission

December 6, 2016 - 18:00

MolMed files a Conditional Marketing Authorisation in the European Union for NGR-hTNF Pdf

December 6, 2016 - 18:00

Highly promising preclinical data in leukaemia and solid tumours for CAR-CD44v6 presented at ASH

December 1, 2016 - 18:00

MolMed and Megapharm enter into a term sheet to commercialise Zalmoxis® in Israel

November 15, 2016 - 18:00

MolMed Board of Directors exercises the power to carry out the capital increase to be reserved to Société Générale of up to no. 42,000,000 ordinary shares pursuant to the agreement named “SEF - Standby Equity Facility”

November 7, 2016 - 18:00

The Board of Directors examines the business performance and approves the results at September 30, 2016

November 7, 2016 - 18:00

Outcome of ordinary and extraordinary Shareholders’ Meeting

October 6, 2016 - 18:00

Resolutions by the Board of Directors of MolMed S.p.A.

September 9, 2016 - 18:00

Data presented at EBMT symposium support Zalmoxis® innovative therapy potential in addressing life-threatening condition

September 1, 2016 - 18:00

MolMed future revenues will benefit from a review of the strategic agreement with GlaxoSmithKline

August 22, 2016 - 18:00

The European Commission grants a Conditional Marketing Authorisation to Zalmoxis®

August 1, 2016 - 18:00

The Board of Directors approves the first half-year financial report ended June 30, 2016

July 1, 2016 - 18:00

MolMed receives positive COMP opinion on the orphan drug designation for Zalmoxis(R)

June 24, 2016 - 18:00

MolMed receives positive CHMP opinion recommending conditional marketing authorisation for Zalmoxis(R)

June 7, 2016 - 18:00

MolMed and Oxford BioMedica reviewed and expanded the existing license agreements’ framework

May 10, 2016 - 18:00

MolMed Board of Directors approved the interim financial report ended March 31, 2016 Pdf

April 19, 2016 - 18:00

Variation in the financial calendar for year 2016

April 18, 2016 - 18:00

Outcome of shareholders' meeting and board of directors

March 31, 2016 - 18:00

MolMed and Takara Bio agreed on terminating the license agreement on TK therapy in Asia countries.

March 28, 2016 - 18:00

No list received at expiry of the extended deadline for submitting lists for the board of statutory auditors

March 25, 2016 - 18:00

Lists of candidates for corporate bodies and prorogation for statutory auditors' lists

March 21, 2016 - 18:00

MolMed and Genenta Science sign a collaboration agreement in the field of gene therapy for the treatment of tumors

March 7, 2016 - 18:00

MolMed’s Board of Directors approved the 2015 draft financial statements and convened the shareholders’ meeting

January 29, 2016 - 18:00

MolMed: organizational structure optimization and further corporate governance strengthening Pdf

January 27, 2016 - 18:00

Financial calendar for fiscal year 2016

December 11, 2015 - 18:00

Outcome of Shareholder's Meeting and subsequent Board of Directors

December 10, 2015 - 18:01

Results published of a study highlighting the role of memory stem T cells in the treatment of leukaemia Pdf

December 1, 2015 - 18:00

MolMed: AIFA granted authorization to manufacture gene therapies for marketing purposes

November 9, 2015 - 18:00

MolMed Board of Directors approved the interim financial report ended 30 September 2015

August 22, 2015 - 18:00

MolMed: corporate governance strengthening

August 3, 2015 - 18:00

MolMed Board of Directors approves the first half-year 2015 financial report

June 3, 2015 - 18:00

MolMed Shareholders' Meeting approves the financial statements at 31 December 2014

June 1, 2015 - 18:00

Presentation at ASCO 2015 of significant survival achieved with NGR-hTNF in the Phase III mesothelioma trial

May 14, 2015 - 18:00

MolMed at ASCO 2015 with three studies on the progress of NGR-hTNF therapy in mesothelioma Pdf

May 11, 2015 - 18:00

MolMed Board of Directors approves the interim financial report at 31 March 2015

April 24, 2015 - 18:00

The Board of Directors approves draft financial statements for 2014 and calls for the General Meeting on 3 June 2015

April 13, 2015 - 18:01

MolMed expands its pipeline by entering the CAR-T field having exercised the option right on San Raffaele Hospital CAR-CD44v6 project

April 9, 2015 - 18:04

Share capital increase successfully completed and fully subscribed for an amount equal to Euro 49,824,834.53

March 30, 2015 - 18:00

End of offering period of the share capital increase, 99.24% subscribed for a total amount of Euro 49.4 million

March 25, 2015 - 18:00

Consob approves the Supplement to the Registration Document, the Information Note and the Summary Note relating to the Share Capital Increase

March 20, 2015 - 18:00

MolMed and GSK sign a strategic collaboration agreement in gene therapy Pdf

March 19, 2015 - 18:00

Resignation of member of the Board of Directors

March 6, 2015 - 18:00

Consob approves the Registration Document, the Information Note and the Summary Note relating to the Share Capital Increase

March 4, 2015 - 18:00

The Board of Directors of MolMed resolves upon the final terms of the Share Capital Increase

February 23, 2015 - 18:00

The Board of Directors of MolMed exercises the power to increase the share capital up to a maximum amount of Euro 50 million Pdf

December 9, 2014 - 18:00

New data presented at ASH confirm the long-term clinical benefit of TK after haploidentical transplantation Pdf

November 10, 2014 - 18:00

MolMed Board of Directors approves the financial report at 30 September 2014

September 29, 2014 - 18:00

MolMed: conclusa la prima tranche dell’aumento del capitale riservato a Société Générale ai sensi dell’accordo “SEF - Standby Equity Facility”

September 26, 2014 - 18:00

MolMed: submitted the utilisation request concerning the first tranche of the capital increase to be reserved to Société Générale pursuant to the agreement named “SEF - Standby Equity Facility” Pdf

September 23, 2014 - 18:00

MolMed Board of Directors exercises the power to carry out the capital increase to be reserved to Société Générale of up to no. 46,000,000 ordinary shares pursuant to the agreement named “SEF - Standby Equity Facility”

September 8, 2014 - 18:00

Outcome of MolMed Shareholders' Meeting

August 1, 2014 - 18:00

Resignation of member of the Board of Directors

July 31, 2014 - 18:00

Resolutions of the Board of Directors

June 4, 2014 - 18:00

Presented at ASCO data on the first patients treated with TK in the Ph III study: survival benefit exceeds trial target

June 3, 2014 - 18:00

New data presented at ASCO on NGR-hTNF: significantly extended survival in mesothelioma and in sarcomas

May 12, 2014 - 18:00

MolMed Board of Directors approves the interim financial report at 31 March 2014

May 5, 2014 - 18:00

MolMed reports top line results of NGR-hTNF in the Phase III trial in malignant pleural mesothelioma

April 15, 2014 - 18:00

Resignation of member of the Board of Directors: clarification

April 14, 2014 - 18:00

Resignation of member of the Board of Directors

April 8, 2014 - 18:00

MolMed Shareholders’ Meeting approves the Financial Statements 2013

April 4, 2014 - 18:00

MolMed share capital increase fully subscribed

April 2, 2014 - 18:00

Share Capital Increase: Offer to Market of the unexercised rights closed early Pdf

April 1, 2014 - 18:00

TK scientific results and regulatory path will be presented today at the 40th annual EBMT meeting

April 1, 2014 - 18:00

Early closure of the offer on the stock exchange of unexercised pre-emptive rights for the subscription of MolMed ordinary shares

March 28, 2014 - 18:00

Share capital increase: conclusion of the offer with pre-emptive rights Pdf

March 28, 2014 - 18:00

TK submission for Conditional Approval validated by EMA

March 7, 2014 - 18:00

MolMed TK therapy submitted for Conditional Marketing Authorisation in EU Pdf

March 5, 2014 - 18:00

Share capital increase against payment with pre-emptive rights: errata corrige

March 3, 2014 - 18:00

Outcome of extraordinary Shareholders' Meeting and meeting of the Board of Directors

February 3, 2014 - 18:00

Update on the registration strategy for the gene therapy TK in Europe and in the United States

January 31, 2014 - 18:00

MolMed Board of Directors calls for extraordinary Shareholders’ Meeting

January 13, 2014 - 18:01

The European Patent Office grants MolMed a new patent on its gene therapy platform